Whether searching for clinically applicable biomarkers, designing a new companion diagnostic (CDx), or honing your study accrual and go-to-market strategies, we have the pharmaceutical development service offerings to set you on the path to success.
The majority of cancer patients today are diagnosed and treated outside the context of clinical research—that is, in the real world.
To improve the efficiency, efficacy, and cost of clinical trials, pharmaceutical companies are using real-world data at each stage of the drug development process.
From biomarker discovery and validation to trial design and label expansion, QIAGEN Real-World Insights (RWI) helps you bridge the gap between actionable insight and real-world action.
Drug development is a lengthy, complex, and costly process, entrenched with a high degree of uncertainty that a drug will actually succeed.
QIAGEN’s Real-World Insights (RWI) portfolio combines robust real-world data from over 160,000 cancer cases and advanced analytics to shorten development timelines, optimize study designs, and improve patient outcomes.
QIAGEN RWI is a professional and personalized service empowering pharmaceutical companies to better understand their target populations. RWI helps you get drugs to market faster, expand their usage to new indications, and confidently answer critical questions, such as:
Choose the best biomarkers and cancer indications for your molecularly targeted therapies
Identify appropriate patient cohorts and enhance your CDx design to improve stratification and success
Expand beyond the one biomarker, one drug paradigm with expert molecular profiling and drug-response analyses
More easily find the right patients and quickly move to recruitment and regulatory acceptance
Create and deliver bespoke RWI projects with a range of flexible options and services tailored to your unique requirements